Sargramostim

Sargramostim Struktur
123774-72-1
CAS-Nr.
123774-72-1
Englisch Name:
Sargramostim
Synonyma:
r-HuGM-CSF;Sargramostim;Sargramostim USP/EP/BP;Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor
CBNumber:
CB3874901
Summenformel:
Molgewicht:
0
MOL-Datei:
Mol file

Sargramostim Eigenschaften

Sicherheit
  • Risiko- und Sicherheitserklärung
  • Gefahreninformationscode (GHS)
HS Code  3504009000
Bildanzeige (GHS) GHS hazard pictograms
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H315 Verursacht Hautreizungen. Hautreizung Kategorie 2 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P280, P302+P352, P321,P332+P313, P362
H319 Verursacht schwere Augenreizung. Schwere Augenreizung Kategorie 2 Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P264, P280, P305+P351+P338,P337+P313P
H335 Kann die Atemwege reizen. Spezifische Zielorgan-Toxizität (einmalige Exposition) Kategorie 3 (Atemwegsreizung) Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" />
Sicherheit
P261 Einatmen von Staub vermeiden.
P271 Nur im Freien oder in gut belüfteten Räumen verwenden.
P280 Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.

Sargramostim Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Sargramostim, a recombinant DNA product, is a granulocyte macrophage colony stimulating factor (GM-CSF) indicated for the treatment of cancer patients after autologous bone marrow transplants. It stimulates immature cells to develop into granulocytes and macrophages and can also switch on mature granulocytes and macrophages.Other indications include improved bone m m w recovery in non-Hodgkins lymphoma and acute lymphoblastic leukemia.

Verwenden

Antineutropenic; hematopoietic stimulant.

Indications

Sargramostim (GM-CSF, Leukine, Prokine) is a human recombinant granulocyte and macrophage colony– stimulating factor that stimulates the production and potentiates the function of both granulocytes and macrophages from hematopoietic progenitor cells. It is used to accelerate bone marrow repopulation after high-dose chemotherapy, radiation therapy, and bone marrow transplantation. Adverse effects associated with sargramostim use include bone pain (similar to that of filgrastim), fatigue, fevers, skin rash, malaise, and fluid retention.

Allgemeine Beschreibung

Sargramostim, rGM-CSF (Leukine), isa glycoprotein commercially produced in genetically engineeredyeast cells. Its polypeptide chain contains 127 aminoacids. It differs from the natural hormone by substitution ofleucine at position 23 and variations in the glycosylation.94Sargramostim is a lineage-nonspecific hematopoietic factor,because it promotes the proliferation and maturation ofgranulocytes (neutrophils and eosinophils) and monocytes(macrophages and megakaryocytes).
The primary indication for sargramostim is in myeloidengraftment following autologous bone marrow transplantationand hematopoietic stem cell transplantation. Handling,storage precautions, and adverse effects are similar to thosefor filgrastim.

Clinical Use

Sargramostim binds to specific receptors on target cellsand induces proliferation, activation, and maturation.Administration to patients causes a dose-related increase inthe peripheral white blood cell count. Unlike G-CSF, GMCSFis a multilineage hematopoietic growth factor that inducespartially committed progenitor cells to proliferate anddifferentiate along the granulocyte and the macrophage pathways.It also enhances the function of mature granulocytesand macrophages/monocytes. GM-CSF increases the chemotactic,antifungal, and antiparasitic activities of granulocytesand monocytes. It also increases the cytotoxicity of monocytestoward neoplastic cell lines and activates polymorphonuclearleukocytes to inhibit the growth of tumor cells.
Sargramostim is used to reconstitute the myeloid tissueafter autologous bone marrow transplant and followingchemotherapy in acute myelogenous leukemia. The preparationdecreases the incidence of infection, decreases the numberof days that antibiotics are required, and decreases theduration of hospital stays.

Sargramostim Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Sargramostim Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 14)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250
1026@dideu.com China 29220 58
Beijing HuaMeiHuLiBiological Chemical 010-56205725
waley188@sohu.com China 12338 58
Copyright 2019 © ChemicalBook. All rights reserved